Jae-hyung Jang, CTO of Glugene Therapeutics (right), poses for a commemorative photo with Professor Jong-sup Lee of Dongguk University after receiving the ‘Good-R&D Award’ in the Gene Therapy Development category for the second consecutive year. The ceremony for the ‘2026 12th Korea Good Company Awards,’ hosted by Money Today, took place on the afternoon of the 13th at the Korea Press Center in Jung-gu, Seoul.
Glugene Therapeutics is a biotechnology company developing AAV (Adeno-Associated Virus) vectors, a core component of advanced biopharmaceutical gene therapies. By integrating sequence- and structure-based AI (Artificial Intelligence) technology, the company has established a competitive edge that enables precise targeting at the cellular level.
A company official stated, “We were previously selected as one of the Top 30 Outstanding R&D Achievements by the Ministry of Health and Welfare.” They added, “By successfully scaling up bioreactor production, we have internalized both vector performance and manufacturing processes, which is driving our vector business forward.”
